Objectives: BAY 57-1293 is a helicase-primase inhibitor (HPI) from a new class of antivirals that are highly efficacious in herpes simplex virus (HSV)-1 animal infection models. Resistant mutants with point mutations in the helicase (UL5) were reported to be present in laboratory isolates at a low frequency of approximately 10
Introduction
Helicase-primase inhibitors (HPI) represent a novel class of herpes simplex virus (HSV) inhibitors that are active in tissue culture, 1 -5 efficacious in animal infection models, 1 -3,5 and several are candidates for clinical development. 6 Previous studies reported the rate of resistance to HPI to be low; 0.5 -4.5 Â 10 26 for BAY 57-1293, 1 10 26 for BILS 22 BS 3 and 10 27 for T157602, 4 compared with approximately 10 24 for nucleosides, e.g. aciclovir or penciclovir. 7 In contrast, we observed that working stocks of two laboratory isolates (HSV-1 SC16 and PDK) contained BAY 57-1293-resistant (15 -40-fold) virions at relatively high frequency (10 24 -10 25 ), although the rate was lower in recently plaque-purified clones, e.g. SC16 cl-2 and PDK cl-1. 8 These observations prompted us to test recent clinical isolates for sensitivity to BAY 57-1293 and frequency of HPI-resistant variants.
Materials and methods

Viruses
A series of 10 anonymous clinical isolates of HSV-1 (A -J) were procured from the Health Protection Agency (HPA), Addenbrooke's Hospital, Cambridge, UK during 2005-06 from apparently immunocompetent patients from skin, oral or genital sites. Swabs were placed in virus-transport medium, inoculated onto MRC-5 cells and the medium was changed after 24 h. When cytopathic effect (CPE) was noted within 48 h, the monolayer was suspended in 1 mL of minimal essential medium and a drop was typed as HSV-1 using a standard indirect fluorescent antibody test with monoclonal antibody obtained from the Division of Virology, Department of Pathology, University of Cambridge. The remaining sample was stored at 2708C.
Antiviral (BAY 57-1293) used for screening
BAY 57-1293, a thiazole amide (molecular mass: 402 Da), was provided as a dry powder by Arrow Therapeutics (London, UK), constituted in DMSO and stored at 1 mg/mL in Dulbecco's modified Eagle's medium (DMEM) at 2208C.
Plaque reduction assays
The 10 isolates (A -J) cultured from MRC-5 cells were tested by a plaque reduction assay (PRA). Aliquots of the specimens were diluted to contain 100 pfu/well and inoculated into 12-well tissue culture plates (Nunc, Denmark) containing approximately 2 Â 10 5
Vero cells/well. After adsorption for 45 min at 378C in humidified 5% CO 2 , a DMEM-overlay, thickened with carboxymethylcellulose (CMC) and containing dilutions of BAY 57-1293, was added to each well. Plaques were enumerated after 48 h.
Screening protocols
The conventional PRA, which tests approximately 100 pfu of sample, could not detect resistant variants at lower frequency (,1%). Therefore, we screened aliquots from the stored MRC-5 virus isolates (titres $10 5 -10 7 pfu/mL) directly for BAY 57-1293 resistance using three different protocols. All isolates were tested using 6-or 12-well plates ( protocols I and II). Isolates D -H were also tested using 75 cm 2 tissue culture flasks (T75) (Nunc) ( protocol III). Approximately 10 4 -10 6 pfu were screened for each sample (limited by the number of Vero cells) for BAY 57-1293-resistant plaques.
Stringent conditions were used: 2 h pre-incubation with BAY 57-1293 (0.8 mM BAY 57-1293 in DMEM) and overlay with 0.8 or 3 mM BAY 57-1293 (4-or 15-fold above ID 90 , respectively); conditions designed to prevent replication of sensitive virus and rule out the spontaneous mutants. Infected monolayers were examined and clearly discernible plaques at 48 h post-infection or 72 h postinfection were marked, enumerated, and the infected cells were aspirated from individual plaques. In the case of T75 flasks, the whole cell sheet was suspended in supernatant, stored at 2708C and retested using PRA in Vero cells. The three screening protocols differed in the following details.
Protocol I. Twelve-well plates and 10-fold dilutions of virus were used. The first six wells of each plate received no drug; three wells received 0.8 mM each and the remaining three wells received 3 mM BAY 57-1293 per well. All drug-treated wells were pre-incubated with 0.8 mM drug in CMC-free medium for 2 h before virus inoculation then overlaid with fresh compound in CMC medium after virus adsorption (Figure 1a ).
Protocol II. In this case, 6-well plates (approximately 10 6 cells/ well) were used and a single dilution of virus (confirmed by back titration). As mentioned earlier, wells were pre-incubated with 0.8 mM BAY 57-1293 for 2 h and medium containing 0.8 or 3 mM drug was added in the overlay after virus adsorption as for protocol I (Figure 1b) .
For isolates F and G, the inoculum was divided among multiple wells and screened for resistance at 3 mM. For the remaining isolates (A -C, I, J), neat virus was inoculated into a single well and compound added at 0.8 mM. In the latter cases, the 48 h yield was also tested for drug resistance by PRA.
Protocol III. In a third experiment, 2 Â 10 5 pfu each of several isolates (D-H) were inoculated into separate T75 tissue culture flasks (approximately 10 7 cells/flask), pre-incubated with 0.8 mM BAY 57-1293 for 2 h, and overlaid with fresh drug-containing medium after virus adsorption. By this method, plaques were not clearly defined because of CPE from the inoculum virus. However, when the cells were harvested at 72 h post-infection, reduced levels of infectious virus were detected (Figure 1c ).
Sequencing of BAY 57-1293-resistant variants
The HSV-1 helicase gene (UL5) was sequenced for BAY 57-1293-resistant variants using a set of eight pairs of overlapping HSV-1-specific primers (designed on the basis of HSV-1 strain 17 sequence; RefSeq accession no. NC 001806). 9 A touchdown PCR 10 was adapted to amplify the UL5 gene in overlapping fragments with a high specificity. PCR amplicons of the expected size were purified and sequenced (both directions using the same primers as for PCR) at the Cambridge Department of Biochemistry by Sanger's dideoxy chain-termination method. The nucleotide and amino acid sequences of UL5 were aligned by ClustalW v 1.82.
Results and discussion
All 10 isolates were sensitive to BAY 57-1293 (Table 1) When larger numbers of pfu were screened, isolate F yielded resistant plaques by three different methods. Using 12-well plates ( protocol I), an estimated 2 Â 10 4 pfu/well was inoculated into the first row; the subsequent two rows received serial 10-fold lower dilutions. Plaques could not be distinguished because of confluent CPE in the first row. However, at 48 h postinfection, one plaque was visible (the well containing 3 mM drug) out of a putative 5.2 Â 10 2 pfu. The number of pfu was deduced from the number of plaques in the first two columns which received no inhibitor. This plaque (BAY-F-r1) was picked for further analysis. Screening 1.4 Â 10 4 pfu (using 6-well plates, protocol II) produced one drug-resistant plaque (BAY-F-r2) at 48 h postinfection which was also aspirated for further analysis.
In the 75 cm 2 flasks ( protocol III), 72 h yields ($2 Â 10 3 pfu/mL) for isolate F or G contained BAY 57-1293-resistant virus (at 30% and 5%, respectively). For the remaining isolates (D, E and H), the infectious virus yields remained sensitive to the drug (0% resistant plaques) and no evidence of resistance was obtained. Thus, isolates F and G yielded resistance to BAY 57-1293 among the 10 isolates screened. Specimens F and G came, respectively, from a vulval swab (female, 25 years) and a swab from an unrelated male (33 years) with penile ulcers. Specimen 
The estimated frequency of drug resistance in isolate F was approximately 10
24 , which is .10 times the highest incidence for BAY 57-1293-resistant viruses reported (4.5 Â 10 26 ). This frequency is similar to aciclovir resistance. 7 Isolate G contained resistant plaques (e.g. BAY-G-r1) at 5 Â 10 26 at the higher limit of the reported range. 1 None of the remaining isolates (A -E and H-J) revealed resistance within the limitations of the available inoculum titres (Table 1) .
Two variants (BAY-F-r1 and BAY-G-r1) from F and G, respectively, were tested by PRA; ID 50 values were .250 mM (i.e. .5000-fold resistant). This suggests that the viruses would be solidly resistant to BAY 57-1293 at therapeutic concentrations.
The UL5 sequences of BAY-F-r1 and BAY-G-r1 confirmed that the isolates were HSV-1 and both were genetically close to the laboratory isolate, SC16, originally isolated in Bristol in the 1960s. Sequence analysis of the UL5 gene revealed a known BAY 57-1293 resistance mutation (K356N) in both variants (Figure 2) . Apart from the resistance mutation, there were no amino acid differences between SC16 and isolate F. There was only one difference (K14R) between isolate G and SC16, which is a known polymorphism between SC16 and other laboratory isolates (Figure 2 ). The existence of six nucleotide differences between the two BAY 57-1293-resistant variants (five silent and one causing K14R in BAY-F-r1) ( Table 2 ) and the fact that isolates F and G were collected on different days and from different geographical locations make it unlikely that the resistant variants could have arisen from laboratory contamination.
BAY-F-r1 and BAY-F-r2 selected using different protocols were found to have the same mutation, Lys-356 (AAG) to Asn (AAT) in UL5, providing further evidence that this mutation preexisted at 10 24 in this clinical isolate and did not arise spontaneously during the selection procedure.
Isolate G contained an identical resistance mutation towards the higher limit of previously reported frequency. It is highly unlikely that this mutant was generated spontaneously during the 72 h incubation in BAY 57-1293 for two reasons: (i) the stringent conditions (discussed earlier) meant that virus replication was inhibited below the level of 1% input titre and (ii) using the same protocol, no drug-resistant variants were detected in isolates E, H or even D with the highest titre of all (5 Â 10 6 pfu/mL) ( Table 1 and Figure 1c) .
The substitution K356N close to UL5 helicase motif IV 11 ( Figure 2 ) has previously been reported to be an HPI resistance mutation conferring a high level of resistance. 1 -3 It is noteworthy that a BAY 57-1293-resistant variant from HSV-1F with the same mutation in UL5 was reported to have similar growth rate and produced equal mortality when compared with wild-type in BALB/c mice. 5 The same Lys-356 residue in UL5, when mutated to Gln 1 or Thr (S. Biswas and H. J. Field, unpublished results), has also been shown to confer resistance to BAY 57-1293. Furthermore, the same substitution in HSV-1 KOS conferred 2500-fold resistance to another HPI, BILS 22 BS, 3 suggesting that the mutants from our clinical isolates are likely to be co-resistant to other HPIs. Interestingly, the K356N KOS mutant was also a fit virus in tissue culture and pathogenic in mice. 3 It is intriguing that isolates F and G contain a mutant with the identical K356N change in UL5 given that .10 different mutations involving 5 different amino acid residues in UL5 confer HPI resistance 1,3 -5 (S. Biswas and H. J. Field, unpublished results). Lys-356 of the GNLMK sequence adjacent to motif IV is conserved across herpesvirus helicases and appears to be important for helicase activity.
It is therefore open to debate whether the K356N mutation had some selective advantage in the patient or during the single cell passage during isolation. An alternative and more likely explanation could be that the K356N mutation is 'neutral' according to Kimura's neutral theory of molecular evolution. 12, 13 The latter proposes that protein and DNA polymorphisms constitute a transient phase of molecular evolution and rejects the notion that the majority of such polymorphisms result from adaptive responses and are actively maintained in the species by some form of natural balancing selection. However, this still begs the question as to why the frequency of this mutation in isolate F should be approximately 100 times the expected range for spontaneous mutations.
The UL5 protein is highly conserved; notwithstanding, we detected a drug-resistant mutant in 2 of 10 independent clinical isolates, and furthermore, a similar high frequency was reported in two of our laboratory working stocks. 8 Our hypotheses to explain these high frequency areas are as follows. (i) Under certain conditions, helicase mutations accelerate growth rate providing an advantage. We have evidence that certain HPIresistant UL5 mutations can increase or decrease viral growth characteristics in tissue culture.
14 This should be testable more rigorously using appropriate tissue culture and animal infection models. For instance, deliberate reconstructions comprising mixtures of parental virus and known HPI-resistant mutants derived from it (e.g. one with faster growth kinetics) will be investigated under defined growth conditions in order to study whether there is an increase in the proportion of the faster-growing mutant over several virus replication cycles. (ii) Virus was exposed to HPI or similar compounds in the patient or during the isolation procedure.
We favour (i) because HPI is at an early stage of development and unlikely to have been available to the patients. However, BAY 57-1293 has structural and functional similarity to the diuretic drug Diamox (acetazolamide). 1 We and others have shown that the HPI BAY 57-1293 is highly efficacious in a 15 However, our present study suggests that it will be particularly important to monitor drug resistance during clinical trials of HPI and further development of these compounds: 'forewarned is forearmed'.
